Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)
Type 2 diabetes (T2DM) and liver disease, mainly metabolic-associated fatty liver disease (MAFLD), previously named non-alcoholic fatty liver disease (NAFLD), coexist in many patients. While physicians were reluctant to use glucose-lowering agents other than insulin in patients with T2DM and liver d...
Main Author: | André J. Scheen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-07-01
|
Series: | Diabetes Epidemiology and Management |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666970623000161 |
Similar Items
-
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
by: Panagiotis Theofilis, et al.
Published: (2022-11-01) -
Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
by: Yunpeng Gu, et al.
Published: (2023-03-01) -
Emerging role of antidiabetic drugs in cardiorenal protection
by: Wen-Jia Fu, et al.
Published: (2024-02-01) -
An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
by: Dora Bianka Balogh, et al.
Published: (2023-04-01) -
Editorial: Pharmacology and treatment methods for NAFLD in the context of diabetes
by: Mohamed Abu-Farha, et al.
Published: (2022-09-01)